New 2-In-1 Powder Aerosol Medicine To Stop Deadly Superbugs In The Lungs

A Purdue University drug formulation incorporates two antibiotics to help fight the global crisis of antimicrobial resistance.

West Lafayette, IN (GLOBE NEWSWIRE) - Purdue University researchers have developed a new approach to treating the fourth-leading cause of death worldwide – lower respiratory infections.

Lung infections, often caused by multi-drug-resistant bacteria, are deadly because the ‘superbugs’ are resistant to all available antibiotics. Even worse, traditional systemic administrations of those antibiotics cannot reach the lung surface to kill the bacteria, and giving a person high doses can produce dangerous and sometimes deadly stress on the kidneys or liver.

Now, Purdue researchers have invented a drug formulation that uses two synergistic antibiotics – colistin and ciprofloxacin – in one single particle that is shown to reach the infection sites in the deep lung area with the capability to kill multi-drug resistant superbugs.

“We are providing a promising option to fight the global crisis of antimicrobial resistance,” said Qi (Tony) Zhou, an assistant professor in Purdue’s College of Pharmacy, who leads the research team. “It has been a worldwide challenge to incorporate two antibiotics with different chemical properties into a single particle. Our novel formulation allows for a much more effective killing of drug-resistant bacteria in the deep lungs as two synergistic antibiotics can be simultaneously delivered to the same infection site.”

Zhou said the technology is designed to save tens of thousands of lives from a variety of deadly lung infections, including people with cystic fibrosis and ventilator-assisted pneumonia.

The Purdue innovation is a dry powder inhaler formulation, which is proving to be more effective and easier to use than conventional inhalation products delivered through nebulizers in most hospitals. Zhou said the Purdue formulation allows for more than 60 percent of drugs to be delivered to the lungs as compared to only 10 percent for a jet nebulizer, along with improved chemical stability. Such an approach can be readily applied to many antibiotic compounds, including those for tuberculosis.

Their work aligns with Purdue's Giant Leaps celebration, celebrating the university’s global advancements in health as part of Purdue’s 150th anniversary. This is one of the four themes of the yearlong celebration’s Ideas Festival, designed to showcase Purdue as an intellectual center solving real-world issues.

The Purdue Office of Technology Commercialization has filed a patent on the innovation, and researchers are looking for partners to continue developing it.

About Purdue Office of Technology Commercialization
The Purdue Office of Technology Commercialization operates one of the most comprehensive technology transfer programs among leading research universities in the U.S. Services provided by this office support the economic development initiatives of Purdue University and benefit the university's academic activities. The office is managed by the Purdue Research Foundation, which received the 2016 Innovation and Economic Prosperity Universities Award for Innovation from the Association of Public and Land-grant Universities. For more information about funding and investment opportunities in startups based on a Purdue innovation, contact the Purdue Foundry at foundry@prf.org. For more information on licensing a Purdue innovation, contact the Office of Technology Commercialization at otcip@prf.org. The Purdue Research Foundation is a private, nonprofit foundation created to advance the mission of Purdue University.

© 2018 GlobeNewswire, Inc. All Rights Reserved.